China Pharma Q3 Revenue Hits $8.3 Million (China)
This article was originally published in PharmAsia News
China Pharma Holdings Inc. announced third quarter revenues of $8.3 million, up more than 65 percent from the same period a year ago. Net income was up 80.73 percent to $3.08 million. China Pharma has primarily focused on the discovery, development, manufacturing and marketing of drugs and supplements in China's growing pharmaceutical market. The company's distribution network spans over 29 provinces and autonomous regions around the country. (Click here for more
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.